Skip to content
Buy This GLP
← Research
Evidence

Semaglutide 2.4 mg Cost-Effectiveness in Japan: A Lifetime Model With Retreatment

A lifetime Markov model put semaglutide 2.4 mg at ¥5,300,580 per quality-adjusted life year in Japan without type 2 diabetes. Modeled gains improved substantially when patients could restart after a capped course.

Editorial profile: Neil SandersBuy This GLP Editorial Team6 min read
Modeled cost per quality-adjusted life yearobesity, no type 2 diabetes¥5,300,580obesity with type 2 diabetes¥7,077,984A simulation, not an observation.The figures improve only if retreatment is allowed.

As in the semaglutide cost-effectiveness analysis for MASH, this study uses a model to project costs and quality-adjusted life years. It follows a hypothetical cohort through simulated health states over decades. Novo Nordisk Pharma funded the study and manuscript, and two authors were company employees [1].

With that established, the interesting part is not the headline ratio. It is what the model had to assume to get there. Japan’s Optimal Use Promotion Guidelines restrict who is eligible for semaglutide 2.4 mg and cap how long they can stay on it. So the authors modeled zero, one or two retreatment courses, with a fixed one-year off-treatment period after each regimen. The two published ratios differ by approximately 1.34-fold. The model estimated a higher ratio in the cohort with type 2 diabetes.

The modeled population was people with a BMI of 35 or more plus at least one obesity-related comorbidity, or a BMI of 27 or more plus at least two obesity-related disorders. The intervention was semaglutide 2.4 mg with diet and exercise, against diet and exercise alone. Our comparison of liraglutide and semaglutide discusses a separate model with its own prices and assumptions. Complication costs in this model came from Japanese sources.

On that point, this desk will not convert the yen figure to dollars. A cost-effectiveness ratio is only meaningful against the willingness-to-pay threshold of the system that produced it, and Japan’s threshold, prices and complication costs are its own. An exchange rate applied to a health-economic ratio produces a number that looks informative and is not.

The authors flag the uncertainties themselves: retreatment efficacy and long-term discontinuation are the weak joints in the model, and both are exactly the places where real data is thin. The article on semaglutide dosing in clinical practice describes what one clinic observed during treatment. Those observations provide context for real-world dosing and do not establish how often patients restart after a treatment cap.

Frequently asked

What did the model conclude?
A cost per quality-adjusted life year of ¥5,300,580 for obesity without type 2 diabetes and ¥7,077,984 with it, from a Japanese public payer perspective discounted at 2%.
Why does retreatment matter so much?
Japan's guidelines cap treatment duration, so the model tested zero, one or two further courses after a one-year gap. Allowing retreatment substantially improved the modeled gains.
Does this tell me what semaglutide is worth where I live?
No. A cost-effectiveness ratio only means something against the willingness-to-pay threshold, prices and complication costs of the system that produced it.

Sources

  1. [1] Kamada Y, Wada S, Matsuda H, Dai Y (2026). Cost-Effectiveness of Semaglutide 2.4 mg for Obesity Disease Management in Japan: A Lifetime Economic Modeling Study Incorporating Retreatment Scenarios Journal of Health Economics and Outcomes Research. PMID 42394652

Where to get it

Price the injectable sellers

The desk lists every seller that publishes an injectable figure, with the advertised price struck against the one a buyer is billed.

Open the price desk →

More in Evidence